Ann: Positive Phase 1 MEND Study Top-Line Results, page-145

So, P 2/3 trial to cost up $20m to $30m. for the full trial.

But, we are looking at a readout at halfway point to support accelerated approval.

Is it fair to say that PAA could get away with circa $15m additional funding from here (on top of the circa $5m as at 31 Dec). To the initial readout.

Less the $1.8m from FightMND. Then we will need about $13m. I note we had 1.1m Dec 2025 options exercised, that is about $200k....

Also seems that the comments re some larger shareholders exercising other options series early may have some merit....

GLTAH.

My sentiment is a hold as I have enough exposure, but, for new players, have a crack - but it could be a wild ride.

DYOR.